Amneal Pharmaceuticals Inc. repurchased its 2.00% senior convertible notes due 2022 through a cash tender offer.
The New Jersey-based generic drugmaker's recently acquired unit, Impax Laboratories LLC, conducted the offer. Impax said about $599.4 million of notes were tendered, representing about 99.9% of the outstanding notes.
RBC Capital Markets acted as dealer manager for the offer.
